-+ 0.00%
-+ 0.00%
-+ 0.00%

Purple Biotech Q1 FY26 net loss narrows to USD 89,000

PUBT·05/15/2026 11:01:04
Listen to the news
Purple Biotech Q1 FY26 net loss narrows to USD 89,000
  • Purple Biotech posted a Q1 net loss of USD 89,000, narrowing from USD 456,000 a year earlier as finance income, net rose to USD 2.16 million from USD 950,000.
  • Operating loss widened to USD 2.25 million from USD 1.41 million, with R&D expense climbing to USD 1.23 million from USD 760,000.
  • G&A costs increased to USD 1.02 million from USD 646,000; cash and cash equivalents fell to USD 5.57 million at March 31 from USD 8.72 million at Dec. 31.
  • Cash and cash equivalents and short-term deposits totaled USD 6.4 million, expected to fund operations into 2027.
  • New patient-derived tumor data showed IM1240 activity across treatment-resistant samples; Purple Biotech formed a CAPTN-3 scientific advisory board and expanded a generative AI collaboration with Converge Bio to speed tri-specific antibody design.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Purple Biotech Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605150700PRIMZONEFULLFEED9721097) on May 15, 2026, and is solely responsible for the information contained therein.